TealeHealth - A boutique healthcare consultancy

With over 40 years experience, with expertise in oncology, immunology with a focus on innovative approaches to Market Access.

Chris Teale


Chris’s career began in operational research in the mining and chemical industries before moving into healthcare. Between 1987 and 2011 he developed extensive practical and academic experience within the pharmaceutical industry, across both Marketing and R&D.  

Since 2012 he has worked in  Pharmaceutical Consultancy (BridgeheadInternational, GfK, and Ipsos)  

In his industry career, he held leadership positions at both Global and European levels, having been Director of Global Pricing and     Market Access (Oncology) at Astra Zeneca, Director Health Economics, Pricing, Reimbursement and Access at Allergan, Commercial Planning Manager at Fisons, and Portfolio Planning Manager at Novartis in Switzerland.

In his market access roles, he developed global pricing and market access strategies for a wide range of products and therapy areas including personalised healthcare products (requiring both pharmaceutical and diagnostic reimbursement).

He also led “Innovate for Access” programmes which identified creative and innovative approaches to overcoming market access hurdles. In his planning roles, he established middle and long-range forecasting models to support the evaluation of in-license and out-license and other business development opportunities; and models to support resource allocation / optimisation in R&D and Marketing.

Within Ipsos, in addition to being senior vice president market access, Chris led the Autoimmune Centre of Expertise which brought together Real World Data and multi-stakeholder (physician, payer, patient, and policy-maker) insights and behaviours across a broad range of   autoimmune diseases.

Whilst at Ipsos, Chris contributed to the publication of significant thought leadership articles, led global webinars, presented work     at ISPOR, and gave podium presentations in 2021/2/3 at the World Evidence Pricing and Access (EPA) Congress.

A list of his most recent publications can be found further down this page

Chris holds a 1st class BSc honours degree in     Mathematics from Newcastle University. He also studied at Loughborough University (Management Information Systems) and INSEAD Business School in France (Marketing for International Business).

He is an occasional lecturer on health economics and pharmaceutical pricing and reimbursement at Kings College London and University of California (San Diego), a member of ISPOR     (International Society for Pharmacoeconomics and Outcomes Research) and PMSA (Pharmaceutical Management Science Association).· 

His pro-active membership of both PMSA(Pharmaceutical Management Science Association), with its predominantly US focus, and European ISPOR, with its different payer archetypes, allows TealeHealth to focus on implementation of methodologically rigorous solutions indiverse healthcare systems.

  • 2023
    TealeHealth founded by Chris Teale
  • 40+
    Years of experience


  • “30 Major Future Challenges inEvidence, Pricing & Access and How to Overcome Them” – Teale.   Presented at World Evidence Pricing Access Congress. March2023.
  • “The Monitor Intervene Predict Value Framework: A Structured Approach to Demonstrating How Digital Health Can Improve Health Outcomes and Reduce Burden of Illness” – Teale. Published in Value & Outcomes Spotlight. Jan/Feb 2023.  Copywrite ISPOR
  • “The Power of Holistic Insight - Understanding why real-world treatment is sub-optimal and what can be done about it” - Teale, Franceschetti, Levent, Duncan.  Sept 2022.
  • "Generating and leveraging RWE to drive pricing & access - The importance of Multiple Data Source Integration and Value Attribution in Multi-Component Disease Management”. Teale. Presented at World Evidence Pricing Access Congress. March 2022.
  • “Changing Paradigms.  The past, present, future of Autoimmune Treatment” – Teale, Baldock.  Global Webinar July 2021.
  • “The future of Pharmaceutical Pricing - Affordability, Evidence, and Value Attribution” – Teale, Boller, Gras.  May 2021
  • Pricing and Access Challenges in the Absence of Data – Rare Diseases, Oncology, and Gene Therapy”. Teale. Presented at World Evidence Pricing Access Congress. March 2021.
  • “The Power of Payer Insights Tracking in times of turbulence and market disruption”. Teale, Gomendio, Global Webinar. 2020
  • “The future of Market Access – 3 Enablers and 3 Disruptors”. Teale, Morrison, Gras et al.   2019
  • “The challenges of optimizing health outcomes and market access in a digital world where Personalized Data and  Precision Medicine collide”. Teale. PMSA European Summit. 2018. Copywrite GfK
  • “Dynamic Pricing: Establishing winning pricing strategies in markets that contain bio-originals, biosimilars, and new innovation” – Teale. PMSA European Summit 2017. Copywrite GfK.                                                                          
All articles and webinars copywrite Ipsos unless otherwise stated.
the next step?

Request a consultation call

Get in touch for an obligation free consultation.
get in touch
“We’ve relied on them on several occasions where client discretion was of the utmost importance”
Joe Thompson — IP Client
“We wouldn't feel comfortable trusting anyone else to represent our company in legal matters”
Helen McNaught — Patent Law Client